Karuna Therapeutics Inc. (KRTX)
NASDAQ: KRTX
· Real-Time Price · USD
329.83
0.09 (0.03%)
At close: Mar 15, 2024, 9:00 PM
Karuna Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 654K | 5.93M | 6.01M | 11.29M | 10.64M | 42.32M | 42.24M | 36.96M | 36.96M | n/a | n/a | n/a |
Cost of Revenue | 1.7M | 1.56M | 1.39M | 1.19M | 864K | 559K | 269K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -1.05M | 4.37M | 4.62M | 10.1M | 9.77M | 41.76M | 41.97M | 36.96M | 36.96M | n/a | n/a | n/a |
Operating Income | -494.78M | -450.23M | -395M | -340.15M | -289.68M | -232.83M | -203M | -172.48M | -143.85M | -140.07M | -108.43M | -91.72M |
Interest Income | 61.18M | 54.46M | 41.39M | 25.29M | 14.18M | 4.75M | 980K | 596K | 502K | 804K | 1.38M | 2.05M |
Pretax Income | -433.01M | -395.18M | -353.02M | -314.27M | -274.92M | -227.55M | -201.52M | -171.52M | -143.8M | -139.81M | -107.72M | -90.35M |
Net Income | -422.19M | -384.58M | -334.5M | -296.29M | -267.81M | -219.56M | -201.44M | -170.91M | -143.81M | -139.85M | -107.76M | -90.39M |
Selling & General & Admin | 131.33M | 108.25M | 95.11M | 85.53M | 76.07M | 71.82M | 65.09M | 57.63M | 52.62M | 41.38M | 35.93M | 32.55M |
Research & Development | 364.1M | 347.91M | 305.91M | 265.91M | 224.25M | 203.34M | 180.16M | 151.82M | 128.2M | 98.69M | 72.5M | 59.17M |
Other Expenses | 588K | 588K | 588K | 588K | 580K | 556K | 531K | 393K | 254K | 131K | 9K | n/a |
Operating Expenses | 495.43M | 456.16M | 401.02M | 351.44M | 300.31M | 275.15M | 245.25M | 209.45M | 180.82M | 140.07M | 108.43M | 91.72M |
Interest Expense | 11.49M | 9.57M | 13.45M | 13.94M | 14.18M | 4.61M | 727K | 237K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 495.43M | 456.16M | 401.02M | 351.44M | 300.31M | 275.15M | 245.25M | 209.45M | 180.82M | 140.07M | 108.43M | 91.72M |
Income Tax Expense | -10.82M | -10.6M | -18.52M | -17.99M | -7.11M | -7.99M | -193K | -827K | -214K | -177K | -63K | 43K |
Shares Outstanding (Basic) | 37.78M | 37.69M | 37.52M | 34.8M | 34.41M | 32.35M | 29.9M | 29.81M | 29.69M | 29.57M | 29.48M | 27.79M |
Shares Outstanding (Diluted) | 37.78M | 37.69M | 37.52M | 34.8M | 34.41M | 32.35M | 29.9M | 29.81M | 29.69M | 29.57M | 29.48M | 27.79M |
EPS (Basic) | -11.39 | -10.6 | -9.57 | -8.99 | -8.45 | -7.17 | -6.76 | -5.76 | -4.93 | -4.88 | -3.87 | -3.35 |
EPS (Diluted) | -11.39 | -10.6 | -9.57 | -8.99 | -8.45 | -7.17 | -6.76 | -5.76 | -4.93 | -4.88 | -3.87 | -3.35 |
EBITDA | -494.33M | -450.23M | -394.71M | -339.59M | -288.87M | -232M | -202.36M | -172.05M | -142.88M | -138.68M | -106.42M | -88.95M |
EBIT | -466.85M | -430.95M | -367.81M | -311.82M | -260.74M | -223.18M | -201.26M | -171.87M | -113.89M | -85.7M | -34.53M | n/a |
Depreciation & Amortization | 1.7M | 1.56M | 1.39M | 1.19M | 1.11M | 1.04M | 859K | 642K | 506K | 318K | 255K | 236K |